Haystack VC

Haystack Oncology is a precision medicine company specializing in the detection of minimal residual disease (MRD) through ultra-sensitive liquid biopsy technology. Spun out from the Johns Hopkins University School of Medicine, the company's proprietary Haystack Duo platform utilizes advanced next-generation sequencing and specialized variant calling chemistry to identify circulating tumor DNA (ctDNA) with high specificity. The technology is designed to help clinicians monitor cancer recurrence and assess treatment efficacy earlier than conventional imaging. In 2023, the company was acquired by Quest Diagnostics to bolster their oncology portfolio and expand access to MRD testing.